fludarabine + cyclophosphamide + LM103 + aldesleukin

This is a **combination regimen** containing fludarabine (a purine analog antimetabolite that inhibits DNA synthesis), cyclophosphamide (an alkylating agent that crosslinks DNA and prevents cell replication), LM103 (insufficient data available to specify exact compound or mechanism), and aldesleukin (a recombinant interleukin-2 used as an immunotherapy to stimulate proliferation and activation of T lymphocytes). Fludarabine and cyclophosphamide are commonly used together in the treatment of hematologic malignancies such as chronic lymphocytic leukemia, often with high response rates due to synergistic cytotoxicity[2][4]. Aldesleukin enhances immune-mediated anti-tumor responses. The addition of LM103 cannot be described in detail due to insufficient information on the substance.

Other names

Autologous tumour infiltrating lymphocytes